Tecentriq and Stroke - a phase IV clinical study of FDA data

Summary:

Stroke is reported as a side effect among people who take Tecentriq (atezolizumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Avastin, and have Hepatocellular carcinoma.

The phase IV clinical study analyzes which people have Stroke when taking Tecentriq. It is created by eHealthMe based on reports of 12,792 people who have side effects when taking Tecentriq from the FDA, and is updated regularly.

What is Tecentriq?

Tecentriq has active ingredients of atezolizumab. eHealthMe is studying from 12,796 Tecentriq users. Check the latest studies of Tecentriq.

What is Stroke?

Stroke (sudden death of a portion of the brain cells due to a lack of oxygen) is found to be associated with 2,389 drugs and 3,009 conditions by eHealthMe. Check the latest studies of Stroke.

On Oct, 27, 2025

12,792 people reported to have side effects when taking Tecentriq.
Among them, 44 people (0.34%) have Stroke.

Among these 44 people:

How long have people been on Tecentriq when they have Stroke? *

What is the gender of people who have Stroke when taking Tecentriq? *

female: 38.1 %
male: 61.9 %

What is the age of people who have Stroke when taking Tecentriq? *

What are other drugs people take besides Tecentriq? *

What are other side effects people have besides Stroke? *

High Blood Pressure: 5 people, 11.36%
Weakness: 4 people, 9.09%
Aortic Arteriosclerosis (hardening of the aortic arteries): 3 people, 6.82%
Atrioventricular Block Complete (heart block complete): 3 people, 6.82%
Blood Creatine Phosphokinase Increased: 3 people, 6.82%
Troponin I Increased: 3 people, 6.82%
Hepatic Enzyme Increased: 3 people, 6.82%
Myasthenia Gravis (a chronic condition that causes muscles to tire and weaken easily): 3 people, 6.82%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 3 people, 6.82%
Myocarditis (inflammation of heart muscle myocardium): 3 people, 6.82%

What are the existing conditions these people have? *

Hepatocellular Carcinoma (liver cancer): 11 people, 25.00%
Lung Cancer - Non-Small Cell (lung cancer): 7 people, 15.91%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 3 people, 6.82%
Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 6.82%
Transitional Cell Carcinoma Metastatic (cancer of urinary inner most layer spreads to other part of body): 2 people, 4.55%
Lung Cancer - Small Cell (lung cancer): 2 people, 4.55%
Colon Cancer Stage Iv: 2 people, 4.55%
Constipation: 2 people, 4.55%
Lung Cancer Metastatic (lung cancer spreads to other parts): 2 people, 4.55%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 2 people, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Tecentriq and have Stroke?

- Check whether Stroke is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tecentriq:

Tecentriq (12,796 reports)

Stroke treatments and more:

Stroke (334,630 reports)

Browse all side effects of Tecentriq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Stroke:

Stroke (2,389 drugs)

Browse all the conditions that are associated with Stroke:

Stroke (3,009 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on atezolizumab (the active ingredients of Tecentriq) and Tecentriq (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.